We have located links that may give you full text access.
Journal Article
Meta-Analysis
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of randomized controlled trials.
International Journal of Cardiology 2016 October 2
OBJECTIVE: After implantation of drug-eluting stents (DES), patients usually receive 6-12months of dual antiplatelet therapy (DAPT). However, the optimal duration of DAPT is controversial. Therefore, we performed a meta-analysis of randomized controlled trials to assess the risks and benefits of different DAPT durations.
METHODS: We searched the literature using MEDLINE, Scopus, EMBASE, ISI Web of Science, Cochrane Library, ClinicalTrials.gov and recent conference proceedings, and included those trials randomizing patients to receive different durations of DAPT after DES implantation and reporting frequencies of cardiovascular and bleeding events. Data from eleven trials were analyzed using RevMan.
RESULTS: Compared to 12-month DAPT treatment, extended DAPT significantly reduced the frequencies of myocardial infarction (OR 0.54 95% CI: 0.43-0.66; p<0.00001) and stent thrombosis (OR 0.36 95% CI: 0.24-0.55; p<0.00001), but the risks of major bleeding (OR 1.54 95% CI 1.22-1.96) and all-cause mortality (OR 1.43 95% CI 1.14-1.81) were substantially increased. There was no significant difference in stroke, cardiovascular mortality or repeat revascularization. Compared to short-term DAPT, 12-month DAPT or longer was associated with increased major bleeds (OR 1.98 95% CI: 1.26-3.11). No significant differences were found in the risk of other primary outcomes.
CONCLUSION: 12-month DAPT appears to be a pragmatic compromise between preventing stent thrombosis and increasing bleeding risk. Patients at high bleeding risk should have shorter duration DAPT while those with low bleeding risk can be considered for DAPT beyond 12months.
METHODS: We searched the literature using MEDLINE, Scopus, EMBASE, ISI Web of Science, Cochrane Library, ClinicalTrials.gov and recent conference proceedings, and included those trials randomizing patients to receive different durations of DAPT after DES implantation and reporting frequencies of cardiovascular and bleeding events. Data from eleven trials were analyzed using RevMan.
RESULTS: Compared to 12-month DAPT treatment, extended DAPT significantly reduced the frequencies of myocardial infarction (OR 0.54 95% CI: 0.43-0.66; p<0.00001) and stent thrombosis (OR 0.36 95% CI: 0.24-0.55; p<0.00001), but the risks of major bleeding (OR 1.54 95% CI 1.22-1.96) and all-cause mortality (OR 1.43 95% CI 1.14-1.81) were substantially increased. There was no significant difference in stroke, cardiovascular mortality or repeat revascularization. Compared to short-term DAPT, 12-month DAPT or longer was associated with increased major bleeds (OR 1.98 95% CI: 1.26-3.11). No significant differences were found in the risk of other primary outcomes.
CONCLUSION: 12-month DAPT appears to be a pragmatic compromise between preventing stent thrombosis and increasing bleeding risk. Patients at high bleeding risk should have shorter duration DAPT while those with low bleeding risk can be considered for DAPT beyond 12months.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app